LUYE PHARMA GROUP LTD. Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
LUYE PHARMA GROUP LTD.
綠 葉 製 藥 集 團 有 限 公 司
(incorporated in the Bermuda with limited liability)
(Stock Code: 02186)
POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 13 JUNE 2017
At the annual general meeting (the ''AGM'') of Luye Pharma Group Ltd. (the ''Company'') held on 13 June 2017, a poll was demanded by the chairman of the AGM for voting on all the proposed resolutions as set out in the notice of the AGM dated 29 April 2017 (the ''AGM Notice'').
As at the date of the AGM, the total number of issued shares of the Company was 3,321,073,843 shares of US$0.02 each, being the total number of shares entitling the shareholders of the Company (the ''Shareholders'') to attend and vote for or against the resolutions at the AGM. There were no restrictions on any Shareholders casting vote on any of the proposed resolutions at the AGM. No Shareholder was required to attend and vote only against the proposed resolutions at the AGM.
The Company's Hong Kong share registrar, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the AGM for the purpose of vote-taking. All the resolutions, where were voted on by poll, were approved by the Shareholders.
POLL RESULTS OF AGM
The poll results in respect of the respective resolutions proposed at the AGM were as follow:
ORDINARY RESOLUTIONS | (Note) | Number of votes cast and approximate percentage of total number of votes cast | |||||||||
For | Against | ||||||||||
1. | To receive and adopt the audited consolidated financial statements of the Company and the reports of the directors of the Company (the ''Directors'') and of the auditors of the Company (the ''Auditors'') for the year ended 31 December 2016. | 2,033,345,011 100.000000% | 0 0.000000% | ||||||||
2. | To declare a final dividend of RMB0.035 HK$0.039) per share for the year ended 31 Dece | (equivalent mber 2016. | to | 2,033,607,011 100.000000% | 0 0.000000% | ||||||
3. | (a) To re-elect Ms. ZHU Yuan Yuan as an executive Director. | 1,924,618,221 94.640617% | 108,988,790 5.359383% | ||||||||
(b) To re-elect Director. | Mr. | SONG | Rui | Lin | as | a | non-executive | 1,915,165,410 94.175787% | 118,441,601 5.824213% | ||
(c) To re-elect Mr. ZHANG Hua Qiao as an independent non- executive Director. | 1,868,499,481 91.881050% | 165,107,530 8.118950% | |||||||||
(d) To re-elect Mr. CHOY Sze Chung Jojo as an independent non-executive Director. | 2,010,651,510 98.871193% | 22,955,501 1.128807% | |||||||||
(e) To authorise the board of directors of the Company (the ''Board'') to fix the remuneration of the Directors. | 2,033,607,011 100.000000% | 0 0.000000% | |||||||||
4. | To re-appoint Ernst & Young as the Auditor to hold office until the conclusion of the next annual general meeting of the Company and to authorise the Board to fix their remuneration for the year ending 31 December 2017. | 2,033,607,011 100.000000% | 0 0.000000% | ||||||||
5. | (A) To give a general mandate to the Directors to allot, issue and deal with additional shares not exceeding 20% of the issued share capital of the Company (the ''Issue Mandate''). | 1,516,606,601 74.577172% | 517,000,410 25.422828% | ||||||||
(B) To give a general mandate to the Directors to repurchase shares not exceeding 10% of the issued share capital of the Company. | 2,033,605,011 99.999902% | 2,000 0.000098% | |||||||||
(C) To extend the Issue Mandate by the number of shares repurchased by the Company. | 1,640,951,231 80.691659% | 392,655,780 19.308341% | |||||||||
Note: For the full text of the above resolutions, please refer to the AGM Notice.
As more than 50% of votes were casted in favour of the above resolutions, all resolutions were duly passed as ordinary resolutions.
By order of the Board
LUYE PHARMA GROUP LTD.
Liu Dian Bo
Chairman
Hong Kong, 13 June 2017
As at the date of this announcement, the executive Directors are Mr. LIU Dian Bo, Mr. YANG Rong Bing, Mr. YUAN Hui Xian and Ms. ZHU Yuan Yuan; the non-executive Director is Mr. SONG Rui Lin; and the independent non-executive Directors are Mr. ZHANG Hua Qiao, Professor LO Yuk Lam, Mr. LEUNG Man Kit and Mr. CHOY Sze Chung Jojo.
Luye Pharma Group Ltd. published this content on 13 June 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 17 June 2017 06:25:17 UTC.
Original documenthttp://www.luye.cn//lvye_en/uploads//2017-06/16/_1497601685_72n8ha.pdf
Public permalinkhttp://www.publicnow.com/view/8B244FE1A69AE6D64A3C7DF8B9D4F7DC9CC5F72A
